Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977926 | 0.96 | HSD11B1 (0.69) | HSD11B1TSHRDPP4LMNASMN1; SMN2 | |
| SCHEMBL5365797 | 0.94 | HSD11B1 (0.72) | HSD11B1TSHRDPP4LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11526870 | 0.92 | HSD11B1 (0.70) | HSD11B1TSHRDPP4LMNASMN1; SMN2 | |
| SCHEMBL1361875 | 0.92 | TSHR (0.58) | HSD11B1TSHRDPP4LMNASMN1; SMN2 | |
| SCHEMBL6554492 | 0.85 | LMNA (0.49) | HSD11B1TSHRDPP4LMNASMN1; SMN2 | |
| Di(Hydroxyethyl)Ether SCHEMBL28932504 | 0.84 | HSD11B1 (0.55) | HSD11B1TSHRDPP4LMNASMN1; SMN2 | |
| SCHEMBL624643 | 0.83 | HSD11B1 (0.63) | HSD11B1TSHRL3MBTL1EPHX2SLC6A4 | |
| SCHEMBL31147495 | 0.83 | KMT2A (0.53) | HSD11B1TSHRLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL627571 | 0.83 | HSD11B1 (0.90) | HSD11B1KMT2AMEN1SLC6A4SLC6A2 | |
| SCHEMBL14525408 | 0.83 | HSD11B1 (0.63) | HSD11B1TSHRL3MBTL1EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| CN-108137508-B | 5-HT2CReceptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10624900-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200078368-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-10272094-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | disclosed |
| CN-108137508-A | 5-HT2CReceptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-3328835-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023679-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023679-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624900-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | HSD11B1 1229/4885TSHR 148/4885DPP4 2805/4885 |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | HSD11B1 1229/4885TSHR 148/4885DPP4 2805/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | HSD11B1 2616/4885TSHR 1091/4885DPP4 2352/4885 |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | HSD11B1 1229/4885TSHR 148/4885DPP4 2805/4885 |
| US-20200078368-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | HSD11B1 1229/4885TSHR 148/4885DPP4 2805/4885 |
| US-10272094-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | HSD11B1 1229/4885TSHR 148/4885DPP4 2805/4885 |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | HSD11B1 1229/4885TSHR 148/4885DPP4 2805/4885 |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | HSD11B1 1229/4885TSHR 148/4885DPP4 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.